[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.48% 82.60 81.40 82.60 82.60 80.40 80.40 163,853 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.7 383

Ekf Diagnostics Share Discussion Threads

Showing 3826 to 3847 of 3950 messages
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
DateSubjectAuthorDiscuss
16/9/2021
07:30
The following is an 'example' of a test to differentiate between SARS-CoV-2, Influenza A and B, RSV collected from one sample and run a single, highly sensitive multiplexed test that detects and differentiates all four viruses - Updated Cepheid SARS-CoV-2, Flu, RSV Test Nabs FDA EUA Sep 14, 2021 | staff reporter NEW YORK – Cepheid announced on Tuesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a new version of its multiplex SARS-CoV-2, influenza, and respiratory syncytial virus test. The new Xpert Xpress COV-2/Flu/RSV plus test adds a third gene target for SARS-CoV-2 to detect future viral mutations of the virus. The addition "delivers broader coverage to mitigate the possible effects of future viral genetic drift," the Danaher subsidiary said in a statement. The test is designed for use on any Cepheid GeneXpert system, which leverages PCR technology, and delivers results in approximately 36 minutes, the Sunnyvale, California-based company said. Cepheid expects to begin shipping the test to customers in the US in the next few weeks. "The ability to collect one sample and run a single, highly sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems," said David Persing, Cepheid's chief medical and technology officer. The first version of the test received EUA from the FDA last year. In July, Cepheid announced a $28 million award from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority for product development related to the multiplex test and a pan-coronavirus test. Full story - hTTps://www.360dx.com/regulatory-news-fda-approvals/updated-cepheid-sars-cov-2-flu-rsv-test-nabs-fda-eua#.YULWsbhKiF4
wan
16/9/2021
06:23
The following is from a combination of memory and quickly taken notes during the EKF Investor Briefing yesterday and should therefore be taken into account accordingly. Please feel free for the other participants/listeners to add, correct or clarify further. Finance - As I previously alluded to, cash generation was affected by unusual circumstances, predominantly one or two large customers extended payment terms, large deposit payment for the new fermentation vessels and securing important/critical inventory out to and including 2023. Ultimately, without these elements cash generation would have been 'much' higher, but a large percentage of those effects from the working capital requirement will flow back. The above shows up in the accounts in Trade and other receivables £16.1m and in CONSOLIDATED STATEMENT OF CASH FLOWS under Changes in working capital. Cash balance of £20m obviously included the above and included the bonus payment to the directors No fund raising or debt required for the targeted earnings enhancing acquisitions (the targets are already revenue generating). Advanced discussions with targets ongoing, with a strong likelihood of news flow accordingly. Other (in no particular order) - Large order received from Peru for Hemo Control product. This was reported in the Interim Results under Hematology. New US order from large private sector partner for product and kitting to enable 500,000 PCR tests per week (for a minimum of 6 months). (I missed a part of this conversation) - Involved in production of a 'one swab' test to differentiate between SARS-CoV-2, Influenza A and B, RSV New large order from Longhorn Vaccines. Ongoing very strong relationship with Longhorn, and under a new agreement EKF is now the distributer for Longhorn products in the US Luke Daum (ex Longhorn Vaccines) , Chief Scientific Officer at EKF Diagnostics, will be full time and will be Mike Salter's (CEO from 1st Oct) righthand man in the US, and will also greatly assist Mike regarding new tests for early disease detection. Large private sector customer moving into diagnostics, including at home diagnostics. EKF also currently manufacturing a molecular enzyme product for this partner to be utilised in diagnostics outside of test kitting. New exciting investment opportunity, in a new market, identified and under advanced discussion with Mount Sinai, if all goes to plan EKF and Mount Sinai investment and dividend in specie next year, and spinoff in 2022.
wan
15/9/2021
21:02
yes it was all good.I like the way they handled the 'large customer' noise which seemed to dominate the May presentation
faz
15/9/2021
19:26
Standout items for me on the call: 1) Possibility of increased orders from the US 2) Potential new spinoff from MS collab next year 3) genetic sequencing testing potential strategic testing - Luke Daum new recruit, others on the call may be able to elaborate better than I
cisk
15/9/2021
18:40
Just a quick note for now.....A truly excellent briefing today, where confirmation of a record August (usually a quite month) for EKF was but one of many highlights, with 'much' more to come beyond that and going forwards. My thanks go to the management and the whole EKF team, on delivering an excellent set of results, and for cultivating the new and exciting growth opportunities. And an even bigger thank you for providing investors with what now looks firmly set to be a very solid and encouraging, if not exciting, long-term investment!
wan
15/9/2021
14:45
Technically consolidation hypothesis holds until the low of the breakout day is not breached. Tic toc.
tongosti
15/9/2021
13:22
I would say this is post breakout consolidation before the next leg up on the back of this afternoon's presentation to investorsIMHO
richman777114
15/9/2021
12:33
Poor mg. his 12 month "paper" profit shrinking. Like I said this is a very very poor follow up day. Those who are able to listen ... listen up!
tongosti
15/9/2021
11:37
V poor follow up day. Observe and act accordingly is the mantra!
tongosti
15/9/2021
08:37
EKF is a shareholder in both Renalytix and Verici and both have been nominated and shortlisted for the AIM Best Technology Award - hTTps://www.aim-awards.co.uk/nominations-overview/
wan
15/9/2021
08:01
Interim Results Presentation - hTTps://www.ekfdiagnostics.com/res/Interims%202021%20v.7.pdf
wan
15/9/2021
07:59
With solid foundations firmly laid and as we enter a new EKF era, and as a very committed long term investor, I am very much looking forward to what that brings.
wan
15/9/2021
07:44
EKF has been nominated and shortlisted in the 2021 AIM Awards in the following categories - Best Use of AIM, Growth Business of the Year and Entrepreneur of the Year - Julian Baines The Shortlist is shown below. Winners will be announced at the AIM Awards 2021 on Thursday 14 October 2021 - hTTps://www.aim-awards.co.uk/nominations-overview/
wan
15/9/2021
00:05
good HY report. Tong already filtered here - looks like he is wasting his time posting anything. Great insights from other posters.
melody9999
14/9/2021
19:16
Bon voyage - thank goodness. Your investing acumen will be sorely missed. Lol.
tongosti
14/9/2021
19:14
Reckon my market timing is better than Tong's without the arrogance. Last time I'll be responding to him - promise. Ive filtered him for good. Thanks guys
mg1982
14/9/2021
19:00
Yeah he's in irritant - constantly telling us what a great trader he is. I prefer to keep a low profile as those that make the most noise are rarely the best traders
davr0s
14/9/2021
18:27
MG1982 Tong is in love with the sound of his own voice, no-one else is the slightest bit interested. Moreover he writes offensively. PLEASE just filter him like most of us have, he (and, I'm afraid, even your responses to him) simply clutter up this board and spoil it for the rest of us. Really the moderator should ban him, though I guess that's too much to ask.
pldazzle
14/9/2021
18:17
And dear don't forget your paper profits are not yours until you cash in. Not that you will get it but just reminding you Toby.
tongosti
14/9/2021
17:52
If someone had held EKF for exactly a year they'd be sitting on at least a 60% gain. I wish all my investments were like this. So yeah Tong you carry on lying so that people can see through you more easily
mg1982
14/9/2021
17:13
Good day in the office chaps. After avoiding a long year on a useless stock, it finally decided to spring up to life today. Goes to show timing is everything. Hola caballeros
tongosti
14/9/2021
17:04
MG1982 - just filter her/him like the rest of us have.
sharw
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 02:20:26